Literature DB >> 2919139

Factors associated with surfactant treatment response in infants with severe respiratory distress syndrome.

A Charon1, W Taeusch, C Fitzgibbon, G B Smith, S T Treves, D S Phelps.   

Abstract

In a prospective, randomized study of 18 infants treated with bovine surfactant (surfactant TA, Tokyo Tanabe Co, Tokyo) for severe respiratory distress syndrome, a lasting response was found in 12 infants (66%), a transient response was found in two (11%), and no response was found in four (22%) when arterial to alveolar PO2 ratios were used to define responses during the first 48 hours after treatment. In contrast, three of 23 control infants (13%) had a transient or lasting "response" to sham treatment (Pediatrics 1987;79:31-37). To determine whether maldistribution of surfactant could explain lack of response or a transient response, surfactant TA was mixed with technetium-99m sulfur colloid (approximately 300 mu Ci per infant), and eight infants with severe respiratory distress syndrome were treated six to 58 hours after birth. Scintigraphy of the lungs was performed three to 15 hours after treatment. Although a lasting response was observed in three infants, a transient one in three, and no response in two, no gross maldistribution of the radioactive label was found. Either lung received from 37% to 62% of the total radioactivity. During the past 3 years, in all infants with severe respiratory distress syndrome who were treated with surfactant (n = 29), poor or transient responses were associated with early patent ductus arteriosus and air leaks (pulmonary interstitial emphysema and pneumothoraces). Pathophysiologic conditions associated with respiratory distress syndrome are more likely to explain suboptimal responses after surfactant treatment than gross maldistribution of surfactant in the lungs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2919139

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

1.  Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Collaborative European Multicentre Study Group.

Authors: 
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

Review 2.  Surfactant treatment for premature babies--a review of clinical trials.

Authors:  C J Morley
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

3.  International randomised controlled trial of patient triggered ventilation in neonatal respiratory distress syndrome.

Authors:  J H Baumer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-01       Impact factor: 5.747

4.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

5.  Surfactant replacement therapy for neonatal respiratory distress syndrome.

Authors:  R Dhanireddy
Journal:  Indian J Pediatr       Date:  1990 Nov-Dec       Impact factor: 1.967

Review 6.  Liquid ventilation in the preterm neonate.

Authors:  C W Yoxall; N V Subhedar; N J Shaw
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 7.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

8.  Chest position and pulmonary deposition of surfactant in surfactant depleted rabbits.

Authors:  R Broadbent; T F Fok; M Dolovich; J Watts; G Coates; B Bowen; H Kirpalani
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-03       Impact factor: 5.747

9.  Prognostic value of the immediate response to surfactant.

Authors:  J Kuint; B Reichman; L Neumann; E S Shinwell
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-11       Impact factor: 5.747

Review 10.  The fate of exogenous surfactant in neonates with respiratory distress syndrome.

Authors:  M Hallman; T A Merritt; K Bry
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.